Detail akcie Cara Therapeutics online

Business Summary: Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Cara Therapeutics Inc revenues decreased 50% to $21M. Net loss increased 39% to $118.5M. Revenues reflect License and milestone fees decrease of 94% to $910K, Commercial supply revenue decrease of 43% to $5.8M, Collaborative revenue decrease of 22% to $12.9M. Higher net loss reflects Research and development - Balancing increase of 21% to $100.3M (expense).